Somewhat Positive Media Coverage Somewhat Unlikely to Impact Rosetta Genomics (ROSG) Stock Price
News articles about Rosetta Genomics (NASDAQ:ROSG) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Rosetta Genomics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.9349782008511 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Rosetta Genomics Ltd. (ROSG) – Oversold Roundup – Wall Street Morning (wallstreetmorning.com)
- Rosetta Genomics Ltd (ROSG) Seeing Increased Volatility in Session – Stonington Post (stoningtonpost.com)
- Rosetta Genomics Ltd. (ROSG) Stock Price -24.78% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- Rosetta Genomics (ROSG) Reports $2M Private Placement – StreetInsider.com (streetinsider.com)
Shares of Rosetta Genomics (NASDAQ:ROSG) traded up 2.86% on Monday, reaching $1.08. 154,658 shares of the company were exchanged. The company’s 50-day moving average price is $1.60 and its 200 day moving average price is $2.37. Rosetta Genomics has a 12 month low of $0.98 and a 12 month high of $10.44. The company’s market cap is $2.02 million.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.